PharMerica (PMC) Raises FY14 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P dip, trading choppy as tech stocks fall
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Goldman Sachs Starts PharMerica (PMC) at Neutral
September 11, 2014 6:52 AM EDTGoldman Sachs initiated coverage on PharMerica (NYSE: PMC) with a Neutral rating and a price target of $29.00.
Analyst Stephan Stewart said, "We are encouraged by PMCs efforts in managing through the loss of its top two clients (15-20% of sales) with (1) organic underlying... More
